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Summary The purpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol Myers Squibb) in the treatment of
drug resistant small-cell lung cancer (SCLC). Patients with SCLC relapsing within 3 months of cytotoxic therapy received paclitaxel
175 mg m-2 intravenously over 3 h every 3 weeks. The dose of paclitaxel was adjusted to the toxicity encountered in the previous cycle. Of 24
patients entered into the study, 24 and 21 were assessable for response and toxicity respectively. There were two early deaths and two toxic
deaths. No complete and seven partial responses (29%) (95%CI 12-51%) were observed and five patients had disease stabilization. The
median survival (n = 21) was 100 days. Life-threatening toxicity occurred in four patients; in others (non)-haematological toxicity was
manageable. Paclitaxel is active in drug-resistant SCLC. Further investigation in combination with other active agents in this poor prognosis
group is appropriate.
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With present-day chemo- and radiotherapy regimens, a major
response with considerable prolongation of survival (Ihde, 1992)
will be achieved in 90-95% ofpatients with small-cell lung cancer
(SCLC). However, in the majority ofthese patients the tumour will
relapse after a shorter or longer treatment-free period. In this situ-
ation, second-line treatment is necessary for adequate palliation.
A multifocal relapse will usually lead to treatment with
chemotherapy (Andersen et al, 1990). Itis then necessary to distin-
guish between patients with tumours that are sensitive and patients
with tumours presumably resistant to cytotoxic agents used in the
induction phase (Giaccone, 1989). Patients relapsing within 3
months ofinduction chemotherapy are considered resistant to the
drugs used in the induction regimen (Postmus et al, 1987; 1993;
Smit et al, 1989). For such patients, second-line treatment should
consist off non-cross-resistant drugs. The poor results currently
obtained by second-line chemotherapy support the view that
failure to identify real non-cross-resistant agents is the primary
reason for lack ofsuccess (Andersen et al, 1990). Further evidence
for this view comes from the fact that, although in most studies
on second-line chemotherapy it is not specifically stated, most
therapy-resistant patients responding to a second-line regimen
have shown a previous response of short duration to first-line
treatment (Smit et al, 1989; Postmus, 1993). Thus, there is a great
need for new active agents in the setting of second-line treatment
in so-called therapy-resistant patients. Moreover, identification of
such agents may lead to the development of more potent first-line
regimens.
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Paclitaxel (taxol) is a new drug with established activity in
resistant solid tumours, such as platinum-resistant ovarian cancer
and anthracylin-resistant breast cancer (Rowinsky et al, 1995).
In addition, it has shown considerable anti-tumour activity in
chemotherapy naive patients with SCLC (Kirschling et al, 1994;
Ettinger et al, 1995). Therefore, we initiated a phase II trial of
paclitaxel (taxol) in patients with clinically resistant SCLC, which
is the subject ofthis report.
PATIENTS AND METHODS
The trial was approved by the local Medical Ethics Committees.
All patients gave informed consent before they were enrolled into
the study.
Eligibility criteria
Patients were considered eligible when they met all of the
following criteria: age between 18 and 75 years; histologically or
cytologically proven SCLC; last cytotoxic treatment less than
3 months before entry; ECOG performance status 0-3; WBC
> 3.0 x 109 1-1; platelet count > 100 x 109 1-1 (unless lower values
were because of bone marrow involvement); creatinine clearance
according to the Cockroft method > 60 ml min-'; bilirubin level
less than 25 ,umol 1-1; and bidimensionally measurable disease.
Exclusion criteria included significant cardiac disease, uncon-
trolled infection and concurrent cytotoxic chemotherapy.
Concurrent radiotherapy was allowed for, provided that not all
measurable lesions were included in the irradiated field.
Pretreatment evaluation
Beforechemotherapy, eachpatient was evaluated with ahistory and
physical examination with assessment of perfomance status, a
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complete blood cell count, liverfunction tests and serumcreatinine,
electrocardiogram (ECG), chest radiograph and/or computerized
tomography ofthe chest and other staging procedures as indicated,
including ultrasonography ofthe liver and bone scintigraphy.
Treatment
Paclitaxel was obtained fromBristol-Myers Squibb, Woerden, The
Netherlands as a concentrated sterile solution, 6 mg ml-' in 5 ml
ampules in polyoxyethylated castor oil (cremophor EL) 50% and
dehydrated alcohol. The full calculated dose of paclitaxel was
diluted in a minimum volume of 250 ml and a maximum volume
of 1000 ml of dextrose 5% or normal saline. To avoid acute
allergic reactions all patients received the following medication:
dexamethasone 8 mg orally 12 and 6 h before paclitaxel, clemas-
tine 2 mg intravenously (i.v.) push 30 min before paclitaxel and
cimetidine 300 mg i.v. push or ranitidine 50 mg i.v. push 30 min
before paclitaxel.
Paclitaxel 175 mg m-2 was administered as a 3-h i.v. infusion
every 21 days. This paclitaxel dose was chosen in view of the
chemotherapeutic and radiotherapeutic pretreatment and the short
interval between the last treatment and inclusion into this study.
The subsequent dose was modified according to toxicity in the
previous course for each individual patient. A dose reduction to
150 mg m-2 was applied when the WBC count was < 1.0 x 1091-
orplatelet counts < 25 x 1091-' for more than 1 week or in the case
of febrile neutropenia. A dose escalation to 200 mg m-2 was
applied when WBC count was > 3.0 x 109 1-' and platelet count
> 75 x 109 1-1 during the previous cycle. When WHO grade IV
myelotoxicity occurs, at this dose level, a dose of 175 mg m-2 was
to be administered in the subsequent cycle.
Therapy was administered for a maximum of five cycles.
Patients wentoff-study in cases ofdiseaseprogression, incomplete
haematological recovery 2 weeks after scheduled re-treatment,
WHO grade III neuropathy or any other non-haematological
toxicity WHO grade IV except alopecia.
Evaluation during treatment
Before each new administration ofpaclitaxel a physical examina-
tion, assessment ofperformance status, laboratory tests, ECG and
chest radiograph or any other investigation necessary for assess-
ment of response was obtained. A complete blood cell count on
days 10 and 14 was obtained between two courses ofpaclitaxel.
Response assessment
A complete response was defined as the complete resolution of
all signs of known disease for a minimum of 4 weeks. A partial
response was defined as a more than 50% reduction in the sum of
the products of the largest perpendicular diameters of all measur-
able lesions for a minimum of 4 weeks. The term stable disease
was given to patients who failed to fulfil the criteria for partial
response in the absence of disease progression. Disease progres-
sion was defined as an increase > 25% in the sum of the products
ofthe largest perpendicular diameters of all measurable lesions or
the occurrence ofany new lesion.
Response duration, time to progression and survival were
measured from the date of initiation oftherapy. All patients were
considered evaluable fortoxicity and response.
Table 1 Patient characteristics
Male/female
Age median, range
Disease extent
LD
ED
Initial performance status
0
1
2
3
Number of previous chemotherapy regimen
1
2
23
Radiotherapy
best response to initial chemotherapy
CR
PR
SD
PD
Median (range) time off cytotoxic therapy (weeks)
Number of metastatic sites
1
2
23
Number of courses total
Median (range)
Number of patients with dose
Escalation
Reduction
20/4
56 (39-73) years
9
15
14
6
3
9
11
4
11
8
13
2
1
4 (0-12)
11
11
2
69
3 (1-5)
14 (18 evaluable)
0
The minimum number ofpatients accrued in the study was that
proposed by Grant et al (1992). Twenty patients were enrolled for
the first stage. If none of the original 20 patients responded, the
drug was inactive and the study terminated. Iffour responses were
observed in the first group of patients the study was to be termi-
nated. If one to three responses were observed, an additional 15
patients were to be enrolled in the second phase. This design
permits the exclusion of a response rate greater than 10.9% at the
90% confidence level if no responses were observed in the first
phase. With greater true response rates, the probability of
declaring a drug active is 0.82 at a true response rate of 16%.
RESULTS
Between December 1994 and June 1996, 24 patients with relapsed
SCLC were treated with paclitaxel. Table 1 lists patient and
disease characteristics. One patient with a mixed adeno/small-cell
carcinoma ofthe lung and one patient with a small-cell carcinoma
ofthe oesophagus with multiple lung metastases were included in
this study. Their median age was 56 years, with a range of 39-73
years; 83% were male and all but three patients were ambulatory
(ECOG performance status 0-2). The median number ofprevious
chemotherapy regimens administered was two, range 1-3. All
patients had received cyclophosphamide, doxorubicin and etopo-
side combination chemotherapy in the induction phase, and a
number ofdifferent regimens as second-line chemotherapy. For 11
of the last group of patients, second-line chemotherapy consisted
of platinum-containing regimens. Eleven patients received radio-
therapy, either to the primary tumour and regional lymph nodes
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Table 2 Toxicity of paclitaxel treatment
A Haematological *Number of courses associated with WHO grade
leucocytes
Platelets Haemoglobin
0 32 54 55
16 3 2
11 5 1 4
III 9 3 1
IV 1 2 1
*Two patients not evaluable (early death), four cycles not evaluable.
B Non-haematological *Number of courses associated with WHO grade
Nausea/vomiting Neuropathy Myalgia** Oedema**
2 17 10 2
11 4 1 13 0
111 1* 0 0 0
*Two patients not evaluable (early death), four cycles not evaluable. **CTC grading; ***during development of brain
metastases.
Table 3 Response, time to progression and survival
Number of patients
Complete response 0
Partial response 7 (29%; 95% Cl 12-51%)
Stable disease 5
Progressive disease 9
Early death 2
Toxic death 1
Response duration Median (range) days 108 (64-243)
Time to progression* Median (range) days 65 (33-243)
Survival" Median (range) days 100 (23-262)
*Seven patients non-evaluable (three patients with disease progression after one course; two ED and one TD); **three
patients non-evaluable (two ED, one TD).
(n = 8) or towards brain metastases (n = 3). The total number of
paclitaxel cycles administered was 69, median 3. In 14 patients it
was possible to escalate the second dose of paclitaxel, although
dose reductions as specified by the protocol were not necessary. In
one patient, a single cycle of paclitaxel had to be delayed for 7
days because of incomplete haematological recovery on day 21.
All other cycles ofpaclitaxel were administered as scheduled.
Toxicity
Complications of treatment were reported according to WHO
criteria. In case these criteria did not apply, common toxicity
criteria were used. Table 2 lists the incidence ofhaematological and
non-haematological toxicities. Two patients were excluded from
this analysis because of rapid disease progression; i.e. before the
first evaluation on day 7; in addition, data from four cycles were
incomplete. The predominant haematological toxicity was non-
cumulative leucocytopenia. WHO grade III/LV leucocytopenia was
observed in 10 out of 63 evaluable cycles. In addition, 5 out of 63
evaluable cycles were associated with WHO gradelII/IV thrombo-
cytopenia. In four patients, life-threatening complications were
encountered. One patient experienced febrile neutropenia during
his fifth cycle ofpaclitaxel, which resolved on antibiotic treatment.
One patient with disease progression developed septic shock
without leucocytopenia or respiratory failure because of lung
oedemaonday 16 ofcycle 2 and wasplaced on a ventilator. He was
weaned and died at home 2 weeks laterbecause oftumour progres-
sion. A third patient, 6 days after his third dose of paclitaxel,
was hospitalized with fever, leucocytopenia (0.2 x 1091-1),
thrombocytopenia (7 x 109 1-1) and elevated liver function tests.
Despite extensive supportive measures, this patient died, although
inremission, onthe second day afterhospital admission. The fourth
patient with a history of cancer-associated thromboembolism
requiring coumarine therapy had an upper gastrointestinal bleeding
on day 5 of cycle 1. His platelet counts were normal but the
bleeding time was > 200 s. Six days after this episode he received a
nasal tube and died the next day, presumably because of massive
aspiration while suffering from leuco- and thrombocytopenia.
Non-haematological toxicity was predominantly peripheral
neuropathy. Transient myalgia required medication in 13 out of63
evaluable cycles. Hypersensitivity reactions were not encountered,
whereas two patients experienced short-lived peripheral oedema.
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Response, time to progression and survival
All available patients had at least one two-dimensional measurable
lesion. Two patients experienced early death, i.e. death before the
first follow-up. These patients are excluded from the survival
analysis, as is the patient who experienced toxic death in his first
cycle. There were no CRs; however, there were seven PRs (29%).
Five patients had SD and nine had progressive disease after one
(n = 4) or two (n = 5) cycles ofpaclitaxel. Ofthe 11 patients who
received platinum-containing chemotherapy for second line treat-
ment, three obtained a PR, three had SD and five progressed after
paclitaxel treatment. In one patient, disease stabilization in a
metastatic site (liver) was observed, whereas a partial response
was observed in the primary tumour. A second patient had a
response in the liver but had progressive brain metastases. In the
other patients included into this study, no evidence of differential
response was observed. The median (range) response duration was
108 (64-243) days for the seven patients who responded to treat-
ment. Median (range) time to progression was 65 (33-243) days
for the 17 patients who received two or more courses ofpaclitaxel.
Twenty-one patients were considered evaluable for survival; the
median survival time was 100 (range 23-262) days.
DISCUSSION
One of the key problems in the management of SCLC is to over-
come the emergence ofdrug-resistant relapses. Few drugs or drug
combinations are capable of effecting tumour regression in the
setting of an early relapse, i.e. within 3 months off induction
chemotherapy. Platinum-based combinations are probably most
effective in this situation, but response rates and response duration
of such regimens are disappointingly low (Andersen et al, 1990).
New drugs with new mechanisms of action are clearly needed for
these poor prognosis patients.
Here, we report the efficacy of paclitaxel 175 mg m-2 every 3
weeks in drug-resistant SCLC. A major response rate of 29%
(95% CI 12-51%) was obtained at the cost ofmanageable toxicity.
In the face ofthe heavy pretreatment, the incidence ofWHO grade
III/IV haematological toxicity was low and mainly characterized
by leucocytopenia. This is also illustrated by the fact that in 14
patients the second dose ofpaclitaxel could be escalated according
to protocol to 200 mg m-2 and no patient required subsequent dose
reduction. There were no signs ofcumulative haematological toxi-
city, which is in accordance with published phase I and II data on
single-agent paclitaxel (Rowinsky et al, 1993). One patient,
however, died in neutropenic sepsis during his third course of
paclitaxel and one patient experienced neutropenic fever in his
fifth course. Non-haematological toxicity consisted mainly of
myalgia and peripheral neuropathy in a minority ofpatients. Other
toxicities were uncommon.
With a response rate of 29%, paclitaxel ranks among the most
active single agents in drug-resistant SCLC. There are two reports
on the activity of single-agent paclitaxel in chemotherapy naive
patients with SCLC. Ettinger et al (1995) treated 36 (32 evaluable)
extensive disease SCLC patients with paclitaxel 250 mg m-2 24-h
infusion every 3 weeks. Owing to a limited supply of the drug,
patients received a maximum offour cycles and were crossed-over
to platinum and etoposide (PE) treatment in cases of disease
progression, stable disease after two courses or partial response
after four courses of paclitaxel. No CRs and 11 (probably 14)
PRs were observed. Interestingly, of the PRs, two converted to
complete responders and eight patients achieved apartial response
after PE treatment. Similar results were obtained in a nearly iden-
tical trial by Kirschling et al (1994). After paclitaxel treatment,
the total response, all partial, rate was 67.5%. Twelve patients
received salvage PE chemotherapy; one CR, three PR and two
major responses among assessable patients (58%) were observed.
These results suggest that there is some degree of non-cross-
resistance between paclitaxel and cisplatin and etoposide. This is
further corroborated by the activity of paclitaxel in platinum-
resistant non-small-cell lung cancer (Ruckdeschel et al, 1994) and
ovarian cancer (Trimble et al, 1993). In addition, there might be
activity in anthracyclin-resistant tumours, as evidenced by
responses observed in this study and anthracyclin-resistant breast
cancer (Abrams et al, 1993).
The biological basis for these observations might be the
different mechanism of resistance for paclitaxel. The taxanes are
unique among tubulin-targeted cytotoxic drugs in that they bind to
polymerized tubulin only (Schiff et al, 1979). Alterations in the
p53 gene, which occurs in over 90% of SCLC (Carbone et al,
1996), probably confers resistance to many cytotoxic agents
(Lowe et al, 1994) used in the clinical management of SCLC, but
do not seem to affect sensitivity for paclitaxel (Hawkins et al,
1996; Wahl et al, 1996; Safran et al, 1996). The most specific
mechanism ofresistance for paclitaxel are alterations in a- and I-
tubulin, resulting in impaired microtubule assembly (Dumontet
et al, 1996). Paclitaxel resistance is also conferred by the MDR
phenotype, at least in vitro (Dumontet et al, 1996), but this type of
drug resistance is uncommon in SCLC in vivo (Lai et al, 1989).
Atypical multidrug resistance owing to decreased or altered levels
of topoisomerase II, which is probably more important for drug
resistance in SCLC, does not seem to affect sensitivity for pacli-
taxel in vitro (Moscow et al, 1996).
Response duration and survival observed in this study was disap-
pointingly short, with most responding patients progressing during
paclitaxel therapy. Such short-lived responses are a common
feature of single-agent therapy in drug-resistant SCLC (Andersen
et al, 1990). Nevertheless, we feel that further studies ofpaclitaxel
combinations in resistant SCLC are warranted. In addition, the data
obtained in this study and preliminary reports on paclitaxel combi-
nations in chemotherapy naive patients suffering from SCLC
(Hainsworth et al, 1996, 1997; Nair et al, 1997) suggest that pacli-
taxel should be investigated in a first-line combination forSCLC. A
good candidate for such a combination is platinum because of its
synergy with paclitaxel in vitro (Jekunen et al, 1994). Such a study
in a similar group ofpatients as described in this report is currently
underway in our institutions. With the finding of a new non-cross-
resistant chemotherapy regimen, the still unanswered question of
the value ofalternating non-cross-resistant chemotherapy might be
adressed in a new study.
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